Citi analyst Samantha Semenkow notes that Argenx (ARGX) shares were weak yesterday following Vyvgart Hytrulo’s inclusion in the FDA’s latest FAERS quarterly update, but would caution investors against over-interpreting the update since the FAERS database in general lacks important details. Argenx is currently running a Phase 4 switching study to better inform how best to transition patients from IVIg to Vyvgart Hytrulo, noted the firm, which views yesterday’s concerns as “overblown” and remains a buyers on weakness. Citi has a Buy rating and $803 price target on Argenx shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se’s Advancements in Neuromuscular Treatment Pipeline Drive Buy Rating
- Argenx selloff overblown, says Wells Fargo
- Argenx Se: Buy Rating Amidst Volatility and Proactive Risk Management
- Argenx weakness presents ‘attractive opportunity,’ says BofA
- FDA flags possible safety signals in new report, says RBC Capital